In this newly created role, Megan will support and grow the day‑to‑day operations of Slade’s pharmacy and compounding services across Australia and New Zealand. She will ensure operational excellence, integrated ways of working, performance against strategy, and strong project management.
Slade announces Megan Clark as Executive Manager for Pharmacy and Compounding
We are pleased to announce the appointment of Megan Clark as Executive Manager – Pharmacy and Compounding (AU/NZ).
A track record of impact at scale
A track record of impact at scale
Over the past four years, Megan has been part of Icon Group’s Australia and New Zealand cancer division. In her role as General Manager Revenue and Service Relationships, Megan has made a significant contribution to our teams and the organisation, bringing strong change leadership, cross functional collaboration and outcome focused program delivery.
Specific achievements include:
- Leading and co‑designing Heidi AI medical transcription to support clinical documentation quality and efficiency.
- Leading Icon Cancer Centre’s (AU/NZ) Operational Excellence Program, embedding continuous improvement and process standardisation.
- Creating a successful Health Fund strategy in our day hospitals, strengthening performance and patient access.
- Remodelled doctor practice management, improving consistency, service experience and data visibility.
Outside of her experience with the group, Megan brings a unique mix of clinical practice and healthcare management having held board positions and executive roles across public and private healthcare.
She has a deep understanding of healthcare strategy, financial modelling, service design and contract negotiation with a strong commitment to driving strategic outcomes and patient-centred care.
At Slade, Megan’s remit spans both Slade Pharmacy and Slade Health operations to ensure service alignment, business integration and delivery against strategic initiatives, strengthening our patient ‑centred model and enabling disciplined growth across the network.
CEO – Pharmacy and Compounding AU/NZ, Russell Hill said the appointment further reinforces the team’s approach to operational excellence.
“Megan’s role further aligns with our integrated leadership structure and commitment to strengthening alignment to enable scalable growth to deliver the best possible services to our patients and partners,” said Russell.
Megan commences in this role from 2 February, 2026.
Please join us in congratulating Megan on this next step in her career.